Viridian Shares Fall 25% After Amgen Data

Viridian Therapeutics stock plunged 25.2% on Monday following Amgen's positive Phase 3 TEPEZZA OBI trial results.
Amgen's TEPEZZA OBI achieved a 77% proptosis response versus 19.6% placebo, outperforming Viridian's elegrobart subcutaneous data.
TEPEZZA OBI showed 76.7% absolute response, placebo‑adjusted 57%, compared with 54%/36% (Q4W) and 63%/45% (Q8W) for elegrobart.
Analysts kept Buy/Outperform ratings on Viridian with price targets of $48, $42 and $50 despite the stock decline.